Cases with CNV alterations (all CNV gain, other than 1 CNV loss liver cancer case and 1 CNV loss breast cancer case) in RRM2B were associated with decreased OS in liver, breast, and prostate carcinoma, and ovarian serous cystadenocarcinoma (Figure 2E). This evidence concerns the gene RRM2B and breast cancer.